NeoStem, Inc. Announces Closing of Public Offering of Common Stock

NEW YORK, Oct. 9, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the closing of a previously announced underwritten public offering of 5,750,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 750,000 shares, offered at a price to the public of $7.00 per share. The gross proceeds to the Company were $40,250,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Help employers find you! Check out all the jobs and post your resume.